
Using Multi-Spectral Imaging with Microchip Electrophoresis to Accurately Screen Newborns for Sickle Cell DiseaseAward last edited on: 4/30/2022
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$256,580Award Phase
1Solicitation Topic Code
839Principal Investigator
Peter GalenCompany Information
Phase I
Contract Number: 1R43HL156685-01A1Start Date: 4/1/2021 Completed: 3/31/2022
Phase I year
2021Phase I Amount
$256,580Public Health Relevance Statement:
PROJECT NARRATIVE Up to 50 to 90% of children born with sickle cell disease (SCD) in economically disadvantaged countries (over 400,000 per year) die before the age of five, although the WHO estimates that 70% could be saved through simple, cost-effective treatments. Early diagnosis starting at birth is critical for implementing effective disease management, but newborn screening is a challenge for low resource environments where a decentralized, point-of-care solution is needed. This project enables our affordable, point-of-care platform based on microchip electrophoresis technology to accurately perform newborn screening.
Project Terms:
Africa ; Africa South of the Sahara ; Sub-Saharan Africa ; Subsaharan Africa ; Age ; ages ; Sickle Cell Anemia ; Hb SS disease ; HbSS disease ; Hemoglobin S Disease ; Hemoglobin sickle cell disease ; Hemoglobin sickle cell disorder ; sickle cell disease ; sickle cell disorder ; sickle disease ; sicklemia ; Southeastern Asia ; Southeast Asia ; beta Globin ; B-globin ; β-globin ; Birth ; Parturition ; Blood ; Blood Reticuloendothelial System ; Child ; 0-11 years old ; Child Youth ; Children (0-21) ; youngster ; High Pressure Liquid Chromatography ; HPLC ; High Performance Liquid Chromatography ; High Speed Liquid Chromatography ; Cities ; Clinical Research ; Clinical Study ; Data Analyses ; Data Analysis ; data interpretation ; Decentralization ; Disease ; Disorder ; Electrophoresis ; Electrophoretic Fractionation ; Environment ; Equipment ; Fetal Hemoglobin ; Fetal Hb ; HbF ; Hemoglobin F ; fetal form of hemoglobin ; fetal globin ; Genetic Counseling ; Genotype ; Ghana ; Gold Coast ; Gold ; Health ; Health Status ; Level of Health ; Hemoglobin concentration result ; hemoglobin level ; Hemoglobinopathies ; Hemoglobin ; Hospitals ; Teaching Hospitals ; India ; Infant ; Newborn Infant ; 0-4 weeks old ; Newborns ; newborn child ; newborn children ; Laboratories ; Modernization ; mortality ; Mutation ; Genetic Alteration ; Genetic Change ; Genetic defect ; genome mutation ; Names ; Neonatal Screening ; Newborn Infant Screening ; newborn screening ; Phenotype ; Race ; Racial Group ; Racial Stocks ; Reagent ; Reference Standards ; Resources ; Research Resources ; Sickle Cell Trait ; HbAS ; Specificity ; Technology ; Testing ; Thalassemia ; Work ; World Health Organization ; Gender ; Caring ; base ; improved ; Clinical ; Phase ; Variant ; Variation ; Ensure ; Training ; Hemoglobin E Disease ; Point of Care Technology ; Point-of-Care Systems ; machine learned ; Machine Learning ; Disorder Management ; Disease Management ; Hereditary ; Inherited ; System ; Country ; innovative technologies ; early detection ; Early Diagnosis ; Gene Alteration ; Gene Mutation ; Accuracy of Diagnosis ; diagnostic accuracy ; trait ; novel ; Economically Deprived ; economic disadvantage ; economically disadvantaged ; underclass ; Economically Deprived Population ; Manpower ; personnel ; Human Resources ; Reporting ; miniaturize ; portability ; Drops ; Microchip Electrophoresis ; Detection ; research clinical testing ; Clinical Evaluation ; Clinical Testing ; clinical test ; Small Business Innovation Research Grant ; SBIR ; Small Business Innovation Research ; Validation ; Development ; developmental ; point of care ; cost ; genetic variant ; Gene variant ; allele variant ; allelic variant ; genomic variant ; sickling ; Population ; innovation ; innovate ; innovative ; commercialization ; screening ; Mendelian disorder ; Mendelian disease ; Mendelian genetic disorder ; monogenic disease ; monogenic disorder ; single-gene disease ; single-gene disorder ; spectrograph ; spectral image ; spectral imagery ; spectrum image ; spectrum imagery ; low and middle-income countries ; LMIC ; screening program ; preventable death ; preventable mortality ; machine learning algorithm ; machine learned algorithm ; in-vitro diagnostics ; detection limit ; cost effective treatment ; cost effective therapy ; point of care testing ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00